Andrea Wagenfeld

ORCID: 0000-0001-9648-4318 · 5 papers in corpus
article 2018
Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies
ChemMedChem ·doi:10.1002/cmdc.201800487

Progesterone plays an important role in the female reproductive system. However, there is also evidence that gynecologic disorders/diseases such as uterine fibroids and endometriosis are progesterone-dependent. Steroidal and non-steroidal s…

article 2018
Exploratory analysis of molecular pharmacodynamic effects of vilaprisan in the endometrium
·doi:10.1016/j.fertnstert.2018.07.399
paratext 2018
Front Cover: Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies (ChemMedChem 21/2018)
·doi:10.1002/cmdc.201800681

The Front Cover shows vilaprisan, a highly selective progesterone receptor modulator (SPRM), bound to the progesterone receptor (PR). Gynecologic diseases such as uterine fibroids and endometriosis depend on progesterone receptor function. …

review 2016
Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies
Expert opinion on therapeutic targets ·doi:10.1080/14728222.2016.1180368

INTRODUCTION: The progesterone receptor plays an essential role in uterine physiology and reproduction. Selective progesterone receptor modulators (SPRMs) have emerged as a valuable treatment option for hormone dependent conditions like ute…

other 2013
BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies
Human Reproduction ·doi:10.1093/humrep/det247

STUDY QUESTION: Does the novel progesterone receptor (PR) modulator BAY 1002670, based on its preclinical pharmacological profile, offer a potential novel treatment option for uterine fibroids? SUMMARY ANSWER: The newly synthesized BAY1002…